…on in children aged 5-11 years (Walter et al. N Engl J Med 2022;386:35-46; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC8609605/pdf/NEJMoa2116298.pdf). This year should see additional data on COVID-19 outcomes in MS patients from the Global Data Sharing Initiative and other databases. Of particular interest would be more details about the higher mortality rate that was reported at last year’s ECTRIMS meeting (Prosperini et al. P759. Evan…
…This poll is currently disabled….
…espondents opted for a platform therapy (DMF or glatiramer acetate). View the video commentary by Dr. Courtney Casserly. https://www.youtube.com/watch?v=VgLWnKBCPsA…
…-reported declines in QoL and activities of daily living or other changes (complete the survey to view the results at https://neuro-sens.com/is-all-ms-progressive/). Such a broader perspective may help to identify the onset of progression earlier and more adequately meet the needs and concerns of patients. The Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo) announced this year should provide additional insights on how…
…mmendations from the National Advisory Committee on Immunization for immunocompromised individuals (www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/statement-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html), it is unclear at present if all provinces will extend access to booster vaccines to MS patients. The U.S. National MS Society has made si…
